MOAB Trial: Optimal Atezolizumab for rGBM (Recurrent Glioblastoma) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if giving patients a drug called atezolizumab before and after surgery for recurrent glioblastoma can improve how their cancer responds.
What is the Condition Being Studied?
Recurrent Glioblastoma
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with glioblastoma (isocitrate dehydrogenase wildtype)
- Have a recurrence after treatment with radiation and temozolomide
- Plan to have surgery
For more information about who can join this study, please contact the study team at 919-684-5301.
Age Group
Adults
What is Involved?
If you join the study, you will:
- Have a physical exam and other tests
- Have magnetic resonance imaging (MRI) scans of the brain
- Have blood draws
- Get atezolizumab before surgery
- Get atezolizumab after surgery
Study Details
Full Title
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
Principal Investigator
Medical Oncologist
Protocol Number
IRB:
PRO00113395
NCT:
NCT06069726
Phase
Phase
N/A
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Call 919-684-5301